Related Experiment Video

Updated: Jan 6, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.1K

Expression and therapeutic potential of TROP2 in cisplatin-resistant germ cell tumors

Laurenz Sperber1, Melanie von Brandenstein1, Carolina Kessler1

  • 1Department of Urology, Uro-Oncology, Robot-Assisted, and Specialized Urologic Surgery, University Hospital Cologne, Kerpener Str. 62, 50937, Cologne, Germany.

Journal of Cancer Research and Clinical Oncology
|October 7, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Antibody–drug conjugateChoriocarcinomaCisplatin resistanceGerm cell tumorsTROP2

More Related Videos

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

13.9K
Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

7.7K

Related Experiment Videos

Last Updated: Jan 6, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.1K
Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

13.9K
Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

7.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

Articles linked to this work by shared authors, journal, and citation graph.

Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Diagnostic performance of the microRNA-371a assay in small testicular masses: a real-world cohort study.

BJU international·2026

NECTIN4 Amplification Is a Frequent Event in Central Nervous System Metastases of Urothelial Carcinoma.

European urology open science·2026

[Diagnosis and treatment of urothelial carcinoma of the bladder with divergent histology].

Urologie (Heidelberg, Germany)·2026

Diagnostic Performance and Clinical Utility of the Uromonitor® Molecular Urine Assay for Urothelial Carcinoma of the Bladder: A Systematic Review and Diagnostic Accuracy Meta-Analysis.

Diagnostics (Basel, Switzerland)·2026

[Indication and outcome of salvage surgery for urogenital malignancies].

Urologie (Heidelberg, Germany)·2026

Time to subsequent therapy (TTST) as an endpoint in clinical studies: development of standardized documentation of subsequent therapy through systematic literature review, expert interviews, and Delphi survey.

Journal of cancer research and clinical oncology·2026

Immune-sparing radiotherapy in solid tumors: radiation-induced lymphopenia, circulating immune-cell dose, and biomarker-guided optimization of radioimmunotherapy.

Journal of cancer research and clinical oncology·2026

Optimized surgical treatment and study management for oncology patients in East Saxony (MISSION4Sax): study protocol of a multicentre pilot study.

Journal of cancer research and clinical oncology·2026

Comment on "Artificial intelligence construction: a review of the bridge between CT imaging features of lung ground-glass nodules adenocarcinoma and carcinogenic driver genes".

Journal of cancer research and clinical oncology·2026

Predictors of the use of psycho-oncological care.

Journal of cancer research and clinical oncology·2026

Slug-positive circulating tumor cells in mesenchymal malignancies: what remains to validate.

Journal of cancer research and clinical oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us